EP0888298B1 - Cyclopentane heptan(ene)säure, 2-heteroarylalkenylderivate als therapeutisches mittel - Google Patents

Cyclopentane heptan(ene)säure, 2-heteroarylalkenylderivate als therapeutisches mittel Download PDF

Info

Publication number
EP0888298B1
EP0888298B1 EP97907627A EP97907627A EP0888298B1 EP 0888298 B1 EP0888298 B1 EP 0888298B1 EP 97907627 A EP97907627 A EP 97907627A EP 97907627 A EP97907627 A EP 97907627A EP 0888298 B1 EP0888298 B1 EP 0888298B1
Authority
EP
European Patent Office
Prior art keywords
dihydroxy
cyclopentyl
pentenyl
compound
hydroxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP97907627A
Other languages
English (en)
French (fr)
Other versions
EP0888298A2 (de
Inventor
Robert M. Burk
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Allergan Sales LLC
Original Assignee
Allergan Sales LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Sales LLC filed Critical Allergan Sales LLC
Publication of EP0888298A2 publication Critical patent/EP0888298A2/de
Application granted granted Critical
Publication of EP0888298B1 publication Critical patent/EP0888298B1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/559—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing hetero atoms other than oxygen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/558—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes
    • A61K31/5585—Eicosanoids, e.g. leukotrienes or prostaglandins having heterocyclic rings containing oxygen as the only ring hetero atom, e.g. thromboxanes having five-membered rings containing oxygen as the only ring hetero atom, e.g. prostacyclin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Definitions

  • the present invention provides cyclopentane heptanoic acid, 2 heteroaryl alkyl or alkenyl derivatives which may be substituted in the 1-position with hydroxyl, alkyloxy, amino and amido groups, e.g. 1-OH cyclopentane heptanoic acid, 2 heteroarylalkenyl derivatives.
  • these derivatives are 7-[5-hydroxy-2-(heteroatom-substituted hydroxyhydrocarbyl)-3-hydroxycyclopentyl] heptanoic or heptenoic acids and amine, amide, ether, ester and alcohol derivatives of said acids wherein one or more of said hydroxy groups are replaced with an ether group.
  • the compounds of this invention are potent ocular hypotensives and are particularly suited for the management of glaucoma.
  • the compounds of this invention are smooth muscle relaxants with broad application in systemic hypertensive and pulmonary diseases; with additional application in gastrointestinal disease, reproduction, fertility, incontinence, shock, inflammation, immune regulation, disorder of bone metabolism, renal dysfunction, cancer and other hyperproliferative diseases.
  • Ocular hypotensive agents are useful in the treatment of a number of various ocular hypertensive conditions, such as post-surgical and post-laser trabeculectomy ocular hypertensive episodes, glaucoma, and as presurgical adjuncts.
  • Glaucoma is a disease of the eye characterized by increased intraocular pressure. On the basis of its etiology, glaucoma has been classified as primary or secondary. For example, primary glaucoma in adults (congenital glaucoma) may be either open-angle or acute or chronic angle-closure. Secondary glaucoma results from pre-existing ocular diseases such as uveitis, intraocular tumor or an enlarged cataract.
  • the underlying causes of primary glaucoma are not yet known.
  • the increased intraocular tension is due to the obstruction of aqueous humor outflow.
  • chronic open-angle glaucoma the anterior chamber and its anatomic structures appear normal, but drainage of the aqueous humor is impeded.
  • acute or chronic angle-closure angle-closure glaucoma the anterior chamber is shallow, the filtration angle is narrowed, and the iris may obstruct the trabecular meshwork at the entrance of the canal of Schlemm. Dilation of the pupil may push the root of the iris forward against the angle, and may produce pupilary block and thus precipitate an acute attack. Eyes with narrow anterior chamber angles are predisposed to acute angle-closure glaucoma attacks of various degrees of severity.
  • Secondary glaucoma is caused by any interference with the flow of aqueous humor from the posterior chamber into the anterior chamber and subsequently, into the canal of Schlemm.
  • Inflammatory disease of the anterior segment may prevent aqueous escape by causing complete posterior synechia in iris bombe, and may plug the drainage channel with exudates.
  • Other common causes are intraocular tumors, enlarged cataracts, central retinal vein occlusion, trauma to the eye, operative procedures and intraocular hemorrhage.
  • glaucoma occurs in about 2% of all persons over the age of 40 and may be asymptotic for years before progressing to rapid loss of vision.
  • topical b-adrenoreceptor antagonists have traditionally been the drugs of choice for treating glaucoma.
  • Eicosanoids and their derivatives have been reported to possess ocular hypotensive activity, and have been recommended for use in glaucoma management.
  • Eicosanoids and derivatives include numerous biologically important compounds such as prostaglandins and their derivatives.
  • Prostaglandins can be described as derivatives of prostanoic acid which have the following structural formula:
  • prostaglandins are known, depending on the structure and substituents carried on the alicyclic ring of the prostanoic acid skeleton. Further classification is based on the number of unsaturated bonds in the side chain indicated by numerical subscripts after the generic type of prostaglandin [e.g. prostaglandin E 1 (PGE 1 ), prostaglandin E 2 (PGE 2 )], and on the configuration of the substituents on the alicyclic ring indicated by ⁇ or ⁇ [[e.g. prostaglandin F 2 ⁇ (PGF 2 ⁇ )].
  • PGE 1 prostaglandin E 1
  • PGE 2 prostaglandin E 2
  • Prostaglandins were earlier regarded as potent ocular hypertensives, however, evidence accumulated in the last decade shows that some prostaglandins are highly effective ocular hypotensive agents, and are ideally suited for the long-term medical management of glaucoma (see, for example, Bito, L.Z. Biological Protection with Prostaglandins , Cohen, M.M., ed., Boca Raton, Fla, CRC Press Inc., 1985, pp. 231-252; and Bito, L.Z., Applied Pharmacology in the Medical Treatment of Glaucomas Drance, S.M. and Neufeld, A.H. eds., New York, Grune & Stratton, 1984, pp.
  • Such prostaglandins include PGF 2 ⁇ , PGF 1 ⁇ , PGE 2 , and certain lipid-soluble esters, such as C 1 to C 2 alkyl esters, e.g. 1-isopropyl ester, of such compounds.
  • the isopropyl ester of PGF 2 ⁇ has been shown to have significantly greater hypotensive potency than the parent compound, presumably as a result of its more effective penetration through the cornea.
  • this compound was described as "the most potent ocular hypotensive agent ever reported” [see, for example, Bito, L.Z., Arch. Ophthalmol. 105, 1036 (1987), and Siebold et.al., Prodrug 5 3 (1989)].
  • prostaglandins appear to be devoid of significant intraocular side effects
  • ocular surface (conjunctival) hyperemia and foreign-body sensation have been consistently associated with the topical ocular use of such compounds, in particular PGF 2 ⁇ and its prodrugs, e.g., its 1-isopropyl ester, in humans.
  • the clinical potentials of prostaglandins in the management of conditions associated with increased ocular pressure, e.g. glaucoma are greatly limited by these side effects.
  • 11,15- 9,15 and 9,11-diesters of prostaglandins for example 11,15-dipivaloyl PGF 2 ⁇ are known to have ocular hypotensive activity. See the co-pending patent applications USSN Nos. 385,645 (filed 07 July 1989, now U.S. Patent 4,994,274), 584,370 (filed 18 September 1990, now U.S. Patent 5,028,624) and 585,284 (filed 18 September 1990, now U.S. Patent 5,034,413).
  • WO-A-96/36599 which has an earlier priority date than the present application but was not published until after the priority date of the present application, discloses a class of prostaglandin analogues for treating ocular hypertension.
  • the compound 7-[3 ⁇ , 5 ⁇ -dihydroxy-2-(3 ⁇ -methoxy-5-(3-thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoic acid is specifically disclosed.
  • R 1 is hydroxyl or a hydrocarbyloxy or heteroatom sustituted hydrocarbyloxy comprising up to 20, e.g. up to 10 carbon atoms, and preferably a lower alkyloxy radical having up to six carbon atoms. At least one of R 1 is a hydrocarbyloxy or heteroatom substituted hydrocarbyloxy.
  • the substituents on the heteroaryl radical may be selected from the group consisting of lower alkyl, e.g. C 1 to C 6 alkyl; halogen, e.g. fluoro, chloro, iodo and bromo; trifluoromethyl (CF 3 ); COR 7 , e.g. COCH 3 ; COCF 3 ; SO 2 NH 2 ; NO 2 ; CN; etc., wherein R 7 is a lower alkyl radical having from 1 to 6 carbon atoms.
  • the present invention relates to an ophthalmic solution comprising a therapeutically effective amount of a compound of formula (I), wherein the symbols have the above meanings, or a pharmaceutically acceptable salt thereof, in admixture with a non-toxic, ophthalmically acceptable liquid vehicle, packaged in a container suitable for metered application.
  • the present invention relates to a pharmaceutical product, comprising
  • a further aspect of the present invention provides methods of treating cardiovascular, pulmonary-respiratory, gastrointestinal, productive, allergic disease, shock and ocular hypertension which comprises administering an effective amount of a compound represented by the formula I.
  • Figure 1 is a schematic of the chemical synthesis of certain 1-carboxylic acid compounds and ester derivatives thereof specifically disclosed as Example 4(a)-(e) and 5(a)-(e) below.
  • Figure 2 is a schematic of the chemical synthesis of certain 1-amido compounds specifically disclosed as Examples 6(b) - (g) below.
  • Figure 3 is a schematic of the chemical synthesis of certain 1-isopropyl ester compounds specifically disclosed as Examples 7(f)-(i), below.
  • Figure 4 is a schematic of the chemical synthesis of certain 15-methoxy-substituted carboxylic acid compounds and isopropyl derivatives thereof.
  • the present invention relates to the use of cyclopentane heptan(ene)oic acid, 2-heteroaryl alkyl or alkenyl derivatives as therapeutic agents, e.g. as ocular hypotensives.
  • the compounds used in accordance with the present invention are encompassed by the following structural formula I: wherein the substituents and symbols are as hereinabove defined.
  • the compounds used in accordance with the present invention have the following structural formula II: wherein the hatched segments represent ⁇ bonds, the solid triangle represents a ⁇ bond and the substituents and symbols are as hereinabove defined.
  • the dotted lines on bonds between carbons 5 and 6 (C-5) and carbons 13 and 14 (C-13) indicate a single or double bond. If two solid lines are used at C-5, or C-13, it indicates a specific configuration for that double bond.
  • Hatched lines used at position C-8, C-9 and C-11 indicate the ⁇ configuration.
  • a triangle at position C-12 represents ⁇ orientation.
  • a more preferred group of the compounds of the present invention includes compounds that have the following structural formula III: wherein Z is selected from the group consisting of O and S, A is selected from the group consisting of N, -CH, and C, R 2 is selected from the group consisting of hydrogen, halogen, and lower alkyl having from 1 to 6 carbon atoms, R 3 and R 4 are selected from the group consisting of hydrogen, halogen, lower alkyl having from 1 to 6 carbon atoms, or, together with R 3 and R 4 forms a condensed aryl ring and R 5 is a lower alkyl having from 1 to 6 carbon atoms.
  • Z is selected from the group consisting of O and S
  • A is selected from the group consisting of N, -CH, and C
  • R 2 is selected from the group consisting of hydrogen, halogen, and lower alkyl having from 1 to 6 carbon atoms
  • R 3 and R 4 are selected from the group consisting of hydrogen, halogen, lower alkyl having from 1 to 6 carbon
  • R 5 is methyl and at least one of R 2 , R 3 or R 4 are independently selected from the group consisting of chloro, bromo and lower alkyl.
  • at least one of R 2 , R 3 or R 4 is chloro or bromo, and more preferably at least one of R 2 , R 3 or R 4 is bromo or at least two of R 2 , R 3 or R 4 are chloro or bromo.
  • at least one of R 2 , R 3 or R 4 is ethyl, propyl, or butyl.
  • Another preferred group includes compounds having the formula IV:
  • the above compounds of the present invention may be prepared by methods that are known in the art or according to the working examples below.
  • the compounds, below, are especially preferred representative of the compounds of the present invention.
  • a pharmaceutically acceptable salt is any salt which retains the activity of the parent compound and does not impart any deleterious or undesirable effect on the subject to whom it is administered and in the context in which it is administered.
  • salts formed with inorganic ions such as sodium, potassium, calcium, magnesium and zinc.
  • compositions may be prepared by combining a therapeutically effective amount of at least one compound according to the present invention, or a pharmaceutically acceptable acid addition salt thereof, as an active ingredient, with conventional ophthalmically acceptable pharmaceutical excipients, and by preparation of unit dosage forms suitable for topical ocular use.
  • the therapeutically efficient amount typically is between 0.0001 and 5% (w/v), preferably 0.001 to 1.0% (w/v) in liquid formulations.
  • solutions are prepared using a physiological saline solution as a major vehicle.
  • the pH of such ophthalmic solutions should preferably be maintained between 6.5 and 7.2 with an appropriate buffer system.
  • the formulations may also contain conventional, pharmaceutically acceptable preservatives, stabilizers and surfactants.
  • Preferred preservatives that may be used in the pharmaceutical compositions of the present invention include, but are not limited to, benzalkonium chloride, chlorobutanol, thimerosal, phenylmercuric acetate and phenylmercuric nitrate.
  • a preferred surfactant is, for example, Tween® 80.
  • various preferred vehicles may be used in the ophthalmic preparations of the present invention. These vehicles include, but are not limited to, polyvinyl alcohol, povidone, hydroxypropyl methyl cellulose, poloxamers, carboxymethyl cellulose, hydroxyethyl cellulose and purified water.
  • Tonicity adjustors may be added as needed or convenient. They include, but are not limited to, salts, particularly sodium chloride, potassium chloride, mannitol and glycerin, or any other suitable ophthalmically acceptable tonicity adjustor.
  • buffers include acetate buffers, citrate buffers, phosphate buffers and borate buffers. Acids or bases may be used to adjust the pH of these formulations as needed.
  • an ophthalmically acceptable antioxidant for use in the present invention includes, but is not limited to, sodium metabisulfite, sodium thiosulfate, acetylcysteine, butylated hydroxyanisole and butylated hydroxytoluene.
  • excipient components which may be included in the ophthalmic preparations are chelating agents.
  • the preferred chelating agent is edentate disodium, although other chelating agents may also be used in place or in conjunction with it.
  • ingredients are usually used in the following amounts: Ingredient Amount (% w/v) active ingredient about 0.001-5 preservative 0-0.10 vehicle 0-40 tonicity adjustor 1-10 buffer 0.01-10 pH adjustor q.s. pH 4.5-7.5 antioxidant as needed surfactant as needed purified water as needed to make 100%
  • the actual dose of the active compounds of the present invention depends on the specific compound, and on the condition to be treated; the selection of the appropriate dose is well within the knowledge of the skilled artisan.
  • the ophthalmic formulations of the present invention are conveniently packaged in forms suitable for metered application, such as in containers equipped with a dropper, to facilitate the application to the eye.
  • Containers suitable for dropwise application are usually made of suitable inert, non-toxic plastic material, and generally contain between 0.5 and 15 ml solution.
  • the triol 4a was diluted with THF (0.8 mL) and lithium hydroxide (0.4 mL of a 0.5 N solution in H 2 O, 0.186 mmol) was added. After 16 h the reaction was acidified with 1N HCl and extracted with EtOAc. The organic portion was washed with brine, dried over MgSO 4 , and concentrated in vacuo . The residue was purified by flash column chromatography (silica gel, 9:1 EtOAc/MeOH) to give 14.0 mg of free acid 5a .
  • Methyl 7-[3 ⁇ ,5 ⁇ -Dihydroxy-2-(3 ⁇ -hydroxy-5-(2-furanyl)-1E-pentenyl) cyclopentyl]-5Z-heptenoate 4f 50 mg, 0.127 mmol was coverted to 12 mg of the title compound 6f.
  • Methyl 7-[3 ⁇ ,5 ⁇ -Dihydroxy-2-(3 ⁇ -hydroxy-5-(4-(2-methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenoate 4 g (65 mg, 0.154 mmol) was converted to 35.8 mg of the tilte compound 6g.
  • the isopropyl esters 7f-i were prepared as illustrated in Scheme 3 from the corresponding carboxylic acids 5f-i, which were prepared in an analogous manner to carboxylic acids 5a-e:
  • Methyl triflate (MeOTF) (97mL, 0.86mmol) was added to a solution of the mixture of alcohols 8f (160 mg, 0.28 mmol) and 2,6-di-t-butyl-pyridine (0.22 mL, 1.00 mmol) in CH 2 Cl 2 (1.5 mL) at 0°C. The reaction was then allowed to warm to room tempeature and stirring was continued for 16 h. After quenching with saturated aqueous NaHCO 3 the reaction was extracted with EtOAc. The organic portion was washed with 1N HCI, brine, dried over MgSO 4 , filtered and concentrated in vacuo . Flash column chromatography (silica gel, 4:1 hexane/EtOAC) provided 123 mg of the mixture of 15 ⁇ , ⁇ -methyl ethers 9f .
  • the ester of 10f (10 mg, 0.025 mmol) was diluted with THF (0.4 mL) and lithium hydroxide (0.2mL of a 0.5 N solution in H 2 O, 0.05 mmol) was added. After 16 h the reaction was acidified with 1N HCl and extracted with EtOAc. The organic portion was washed with brine, dried over MgSO 4 , and concentrated in vacuo . The residue was purified by flash column chromatography (silica gel, 9:1 MeOH/EtOAc) to furnish 5.0 mg of the carboxylic acid 11f .
  • ester 10f (20 mg, 0.05 mmol) and potassium carbonate (20.4 mg, 0.15 mmol) in anhydrous isopropanol (3.0 mL) was heated at 100°C for 16 h. The reaction was concentrated in vacuo and the residue as stirred with 1:1 EtOAc/H 2 O ( ⁇ 20 mL) for 0.5 h. The organic portion was separated, dried over MgSO 4 , filtered and concentrated in vacuo . Purification of the residue by flash column chromatography (silica gel, 2:1 hexane/EtOAc) provided 20.2 mg of the title compound 12f .
  • FP-activity was measured as contraction of the isolated feline iris sphincter.
  • EP 4 -activity was measured as relaxation of smooth muscle of isolated rabbit jugular vein.
  • TP-vasoconstrictor activity was measured as contraction of rings of the isolated rat thoracic aorta.
  • Effects on platelets from healthy human donors were measured by incubating platelet-rich plasma with the compounds described herein. Inhibition of aggregation was determined by the ability of the compounds described herein to inhibit platelet aggregation in platelet-rich plasma induced by 20 ⁇ M adenosine diphosphate (ADP).
  • ADP adenosine diphosphate
  • FP VASC vascular endothelium in the rabbit jugular vein preparation. Since such agents would be vasodilators they have potential in hypertension and any disease where tissue blood perfusion is compromised. Such indications include, but are not limited to, systemic hypertension, angina, stroke, retinal vascular diseases, claudication, Raynauds disease, diabetes, and pulmonary hypertension.
  • the effects of certain of the compounds of the working examples on intraocular pressure are also provided in the following tables.
  • the compounds were prepared at the said concentrations in a vehicle comprising 0.1% polysorbate 80 and 10 mM tris (hydroxy methyl) aminomethane hydrochloride (TRIS) base. Dogs were treated by administering 25 ⁇ l to the ocular surface, the contralateral eye received vehicle as a control. Intraocular pressure was measured by applanation pneumatonometry. Dog intraocular pressure was measured immediately before drug administration and at 6 hours thereafter.
  • the compounds of the invention may also be useful in the treatment of various pathophysiological diseases including acute myocardial infarction, vascular thrombosis, hypertension, pulmonary hypertension, ischemic heart disease, congestive heat failure, and angina pectoris, in which case the compounds may be administered by any means that effect vasodilation and thereby relieve the symptoms of the disease.
  • administration may be by oral, transdermal, parenterial, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, or buccal routes.
  • the compounds of the invention may be used alone, or in combination with other of the known vasodilator drugs.
  • the compounds of the invention may be formulated into an ointment containing 0.10 to 10% of the active ingredient in a suitable base of, for example, white petrolatum, mineral oil and petrolatum and lanolin alcohol.
  • suitable bases will be readily apparent to those skilled in the art.
  • the pharmaceutical preparations of the present invention are manufactured in a manner which is itself known, for example, by means of conventional dissolving or suspending the compounds, which are all either water soluble or suspendable.
  • the pharmaceutical preparations which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules make of gelatin and a plasticizer such as glycerol or sorbitol.
  • the push-fit capsules can contain the active compounds in liquid form that may be mixed with fillers such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds are preferably dissolved or suspended in suitable liquids, such as in buffered salt solution.
  • stabilizers may be added.
  • the pharmaceutical preparations may contain suitable excipients to facilitate the processing of the active compounds into preparations that can be used pharmaceutically.
  • suitable excipients to facilitate the processing of the active compounds into preparations that can be used pharmaceutically.
  • pharmaceutical preparations for oral use can be obtained by adhering the solution of the active compounds to a solid support, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragee cores.
  • Suitable excipients are, in particular, fillers such as sugars, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as inders such as starch, paste using for example, maize starch, wheat starch, rich starchy, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropylmethylcellulose, sodium carboxymethylcellulose, and/or polyvinyl pyrrolidone.
  • fillers such as sugars, for example lactose or sucrose, mannitol or sorbitol, cellulose preparations and/or calcium phosphates, for example tricalcium phosphate or calcium hydrogen phosphate, as well as inders such as starch, paste using for example, maize starch, wheat starch, rich starchy, potato starch, gelatin, tragacanth, methyl cellulose, hydroxypropyl
  • disintegrating agents may be added such as the above-mentioned starches and also carboxymethyl-starch, crosslinked polyvinyl pyrrolidone, agar, or algenic acid or a salt thereof, such as sodium alginate.
  • Auxiliaries are, above all, flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, such as magnesium stearate or calcium stearate, and/or polyethylene glycol.
  • Dragee cores are provided with suitable coatings which if desired, are resistant to gastric juices.
  • concentrated sugar solutions may be used, which may optionally containing gum arabic, talc, polyvinyl pyrrolidone, polyethylene glycol and/or titanium dioxide, lacquer solutions and suitable organic solvents or solvent mixtures.
  • suitable cellulose preparations such as acetylcellulose phthalate or hydroxypropylmethyl-cellulose phthalate, are used.
  • Dye stuffs or pigments may be added to the tables or dragee coatings, for example, for identification or in order to characterize combinations of active compound doses.
  • Suitable formulations for intravenous or parenteral administration include aqueous solutions of the active compounds.
  • suspensions of the active compounds as oily injection suspensions may be administered.
  • Aqueous injection suspensions may contain substances which increase the viscosity of the suspension include, for example, sodium carboxymethyl cellulose, soribitol, and/or dextran.
  • the suspension may also contain stabilizers.

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Cosmetics (AREA)
  • Fats And Perfumes (AREA)

Claims (20)

  1. Verbindung der Formel 1:
    Figure 00350001
    bei der die Anlagerungen mit einer gewellten Linie entweder die alpha (α) oder beta (β)-Konfiguration anzeigen; bei der die gestrichelten Bindungen eine Doppelbindung oder eine Einfachbindung repräsentieren, bei der R ein Heteroaryl- oder ein substituiertes Heteroaryl-Radikal ist, bei der R1 Hydroxyl- oder Hydrocarbyloxy oder mit einem Heteroatom substituiertes Hydrocarbyloxy ist, das bis zu 20 Kohlenstoffatome umfasst, bei der X aus der Gruppe ausgewählt ist, die aus OR6 und -N(R6)2 besteht, wobei R6 aus der Gruppe ausgewählt ist, die aus Wasserstoff, einem niederen Alkylradikal mit von 1 bis 6 Kohlenstoffatomen,
    Figure 00350002
    besteht, wobei R5 ein niederes Alkylradikal mit von 1 bis 6 Kohlenstoffatomen ist, und bei der Y =O ist oder zwei Wasserstoffradikale repräsentiert und weiterhin vorausgesetzt, daß zumindest ein R1 Hydrocarbyloxy oder mit einem Heteroatom substituiertes Hydrocarbyloxy ist, oder ein pharmazeutisch akzeptables Salz hiervon, wobei jedoch die Verbindung 7-[3α, 5α-dihydroxy-2-(3α-methoxy-5-(3-thienyl)-1E-pentenyl)cyclopentenyl]-5Z-Heptensäure ausgeschlossen ist.
  2. Verbindung nach Anspruch 1, die die Formel II aufweist:
    Figure 00360001
    bei der die schraffierten Abschnitte α-Bindungen repräsentieren und das volle Dreieck eine β-Bindung repräsentiert.
  3. Verbindungen nach Anspruch 2, bei der der Substituent am Heteroarylradikal aus der Gruppe ausgewählt ist, die aus niederem Alkyl mit von 1 bis 6 Kohlenstoffatomen, Halogen, Trifluormethyl (CF3), COR7, COCF3, SO2NH2, NO2 und CN besteht, wobei R7 eine niederes Alkylradikal mit von 1 bis 6 Kohlenstoffatomen ist.
  4. Verbindung nach Anspruch 2, die die Formel III aufweist:
    Figure 00360002
    wobei Z aus der Gruppe ausgewählt ist, die aus O und S besteht, A aus der Gruppe ausgewählt ist, die aus N, -CH, und C besteht, R2 aus der Gruppe ausgewählt ist, die aus Wasserstoff, Halogen und einem niederen Alkyl mit von 1 bis 6 Kohlenstoffatomen besteht, bei der R3 und R4 aus der Gruppe ausgewählt sind, die aus Wasserstoff, Halogen, niederem Alkyl mit von eins bis sechs Kohlenstoffatomen besteht, oder, zusammen mit
    Figure 00370001
    R3 und R4 einen kondensierten Arylring bildet und R5 ein niederes Alkyl mit von 1 bis 6 Kohlenstoffatomen ist.
  5. Verbindung nach Anspruch 4, die durch die Formel
    Figure 00370002
    repräsentiert wird.
  6. Verbindung nach Anspruch 5, bei der X -OH oder -NH2 ist.
  7. Verbindung nach Anspruch 5, bei der Y =O und X -OH ist.
  8. Verbindung nach Anspruch 5, bei der Y =O und X Isopropoxy ist.
  9. Verbindung nach Anspruch 5, bei der Z S ist.
  10. Verbindung nach Anspruch 5, bei der Z O ist.
  11. Verbindung nach Anspruch 9, die 7-[3α, 5α-Dihydroxy-2-(3α-methoxy-5-(3-(2-methyl)thienyl-1 E-pentenyl)cyclopentyl]-5Z-heptensäure ist.
  12. Verbindung nach Anspruch 10, die 7-[3α, 5α-Dihydroxy-2-(3α-methoxy-5-(2-furanyl)-1E-pentenyl)cyclopentyl]-5Zheptensäure ist.
  13. Verbindung nach Anspruch 10, die Isopropyl 7-[3α, 5α-Dihydroxy-2-(3α-methoxy-5-(2-furanyl)-1Epentenyl)cyclopentyl]-5Z-heptenoat ist.
  14. Verbindung, die aus der Gruppe ausgewählt ist, die aus
    7-[3α, 5α,-Dihydroxy-2-(3α-hydroxy-5-(2-(3-chloro)benzothienyl-1E-pentenyl)cyclopentyl]-5Z-heptensäure;
    7-[3α, 5α-Dihydroxy-2-(3α-hydroxy-5-(5-(2,3-dibromo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptensäure;
    7-[3α, 5α-Dihydroxy-2-(3α-hydroxy-5-(2-methyl)furanyl-1Epentenyl)cyclopentyl]-5Z-heptensäure;
    7-[3α, 5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2,5-dibromo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptensäure;
    7-[3α, 5α-Dihydroxy-2-(3α-hydroxy-5-)5-(2-bromo-3-methyl)-thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptensäure;
    7-[3α, 5α-Dihydroxy-2-(3α-hydroxy-5-(5-(2,3-dibromo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamid;
    7-[3α, 5α-Dihydroxy-2-(3α-hydroxy-5-(5-(2-methyl)furanyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamid;
    7-[3α, 5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2,5-dibromo)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamid;
    7-[3α, 5α-Dihydroxy-2-(3α -hydroxy-5-(5-(2-bromo-3-methyl)-thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamid;
    7-[3α, 5α-Dihydroxy-2-(3α-hydroxy-5-(2-furanyl)-1Epentenyl)cyclopentyl]-5Z-heptenamid;
    Methyl 7-[3α, 5α-Dihydroxy-2-(3α-hydroxy-5-(2-furanyl)-1Epentenyl)cyclopentyl]-5Z-heptenoat;
    7-[3α, 5α-Dihydroxy-2-(3α-hydroxy-5-(4-(2-methyl)thienyl)-1E-pentenyl)cyclopentyl]-5Z-heptenamid;
    Isopropyl 7-[3α, 5α-Dihydroxy-2-(3α-hydroxy-5-(2-furanyl)-1Epentenyl)cyclopentyl]-5Z-heptenoat;
    Isopropyl 7-[3α, 5α-Dihydroxy-2-(3α-hydroxy-5-(4-(2-methyl)thienyl-1E-pentenyl)cyclopentyl]-5Z-heptenoat;
    Isopropyl 7-[3α, 5α-Dihydroxy-2-(3α-hydroxy-5-(5-(2-methyl)thienyl)-1E-pentenyl)-cyclopentyl]-5Z-heptenoat;
    Isopropyl 7-[3α, 5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2-methyl)thienyl)-1E-pentenyl)-cyclopentyl]-5Z-heptenoat;
    7-[3α, 5α-Dihydroxy-2-(3α-hydroxy-5-(3-(2-methyl)thienyl)-1Epentenyl)cyclopentyl]-5Z-heptensäure;
  15. Eine wie einem der vorhergehenden Ansprüche definierte Verbindung zur Verwendung in der Behandlung der okularen Hypertension bei einem Säugetier.
  16. Verbindung, wie in einem der Ansprüche 1 bis 14 definiert, zur Verwendung als Relaxans der glatten Muskulatur.
  17. Wie in einem der Ansprüche 1 bis 14 definierte Verbindung zur Verwendung in der Behandlung einer systemischen hypertensiven und pulmonaren Erkrankung oder einer gastrointestinalen Erkrankung, der Inkontinenz, des Schocks, einer Entzündung, einer Störung des Knochenmetabolismus, einer renalen Dysfunktion, von Krebs und einer hyperproliferativen Erkrankung und zur Verwendung in der Immunregulation und in Therapien, die mit der Reproduktion und Fertilität assoziiert sind.
  18. Verwendung einer wie in einem der Ansprüche 1 bis 14 definierten Verbindung zur Herstellung eines Medikamentes für eine wie in einem der Ansprüche 15 bis 17 definierte Verwendung.
  19. Ophthalmische Lösung, die eine therapeutisch wirksame Menge einer Verbindung von Formel I, wie in einem der Ansprüche 1 bis 14 definiert, in Mischung mit einem untoxischen, ophtalmisch verträglichen flüssigen Träger umfasst, verpackt in einem Behälter, der zur abgemessenen Verabreichung geeignet ist.
  20. Pharmazeutisches Produkt, das einen Behälter umfasst, der zur Abgabe des Inhalts dieses Behälters in einer abgemessenen Form und eine ophthalmische Lösung in diesem Behälter umfasst, die eine Verbindung der Formel I, wie in einem der Ansprüche 1 bis 14 definiert, in Mischung mit einem untoxischen, ophtalmisch verträglichen flüssigen Träger umfasst.
EP97907627A 1996-02-29 1997-02-20 Cyclopentane heptan(ene)säure, 2-heteroarylalkenylderivate als therapeutisches mittel Expired - Lifetime EP0888298B1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/608,794 US5741810A (en) 1996-02-29 1996-02-29 Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
US608794 1996-02-29
PCT/US1997/002313 WO1997031895A2 (en) 1996-02-29 1997-02-20 Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents

Publications (2)

Publication Number Publication Date
EP0888298A2 EP0888298A2 (de) 1999-01-07
EP0888298B1 true EP0888298B1 (de) 2002-07-17

Family

ID=24438034

Family Applications (1)

Application Number Title Priority Date Filing Date
EP97907627A Expired - Lifetime EP0888298B1 (de) 1996-02-29 1997-02-20 Cyclopentane heptan(ene)säure, 2-heteroarylalkenylderivate als therapeutisches mittel

Country Status (13)

Country Link
US (4) US5741810A (de)
EP (1) EP0888298B1 (de)
JP (1) JP4226650B2 (de)
KR (1) KR19990087352A (de)
CN (1) CN1133434C (de)
AT (1) ATE220664T1 (de)
AU (1) AU725145B2 (de)
BR (1) BR9707892A (de)
CA (1) CA2247208A1 (de)
DE (1) DE69714023T2 (de)
ES (1) ES2178756T3 (de)
HK (1) HK1017671A1 (de)
WO (1) WO1997031895A2 (de)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6124344A (en) * 1993-12-28 2000-09-26 Allergan Sales, Inc. Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
WO1998021180A1 (en) * 1995-06-07 1998-05-22 Alcon Laboratories, Inc. Conformationally rigid aryl- or heteroaryl prostaglandins for use in glaucoma therapy
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents
DE69824966T2 (de) * 1997-09-09 2005-04-07 Duke University Aromatische c16-c20-substituierte tetrahydro-prostaglandine verwendbar wie fp agoniste
WO1999012898A1 (en) * 1997-09-09 1999-03-18 The Procter & Gamble Company Aromatic c16-c20-substituted tetrahydro prostaglandins useful as fp agonists
CN1269785A (zh) * 1997-09-09 2000-10-11 普罗克特和甘保尔公司 用作fp激活剂的芳香族c16－c20－取代四氢前列腺素
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
AU3385900A (en) * 1999-03-05 2000-09-21 Procter & Gamble Company, The Method of increasing bone volume using non-naturally-occurring selective fp agonist and dito ep1 agonist prostaglandin derivatives
JP4834224B2 (ja) 1999-03-05 2011-12-14 デューク ユニバーシティ Ｃ１６不飽和ｆｐ−選択的プロスタグランジン類縁体
US6826874B2 (en) * 1999-06-30 2004-12-07 Nippon Steel Corporation Buckling restrained braces and damping steel structures
TWI290470B (en) 1999-12-01 2007-12-01 Sankyo Co The composition for treating glaucoma
US20020037914A1 (en) 2000-03-31 2002-03-28 Delong Mitchell Anthony Compositions and methods for treating hair loss using C16-C20 aromatic tetrahydro prostaglandins
US20020013294A1 (en) * 2000-03-31 2002-01-31 Delong Mitchell Anthony Cosmetic and pharmaceutical compositions and methods using 2-decarboxy-2-phosphinico derivatives
US20020172693A1 (en) * 2000-03-31 2002-11-21 Delong Michell Anthony Compositions and methods for treating hair loss using non-naturally occurring prostaglandins
US20020146439A1 (en) * 2000-03-31 2002-10-10 Delong Mitchell Anthony Compositions and methods for treating hair loss using oximyl and hydroxylamino prostaglandins
US6248783B1 (en) * 2000-09-20 2001-06-19 Allergan Sales, Inc. Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents
US6531504B2 (en) * 2001-05-17 2003-03-11 Allergan, Inc. Prostanoic acid derivatives as agents for lowering intraocular pressure
US6476064B1 (en) * 2001-06-13 2002-11-05 Allergan, Inc. Cyclopentane heptan(ene) acyl sulfonamide, 2-alkyl or 2-arylalkyl, or 2-heteroarylalkenyl derivatives as therapeutic agents
US20040254230A1 (en) * 2001-12-03 2004-12-16 Ogidigben Miller J. Method for treating ocular hypertension
US9216183B2 (en) 2002-02-04 2015-12-22 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
US7351404B2 (en) 2002-02-04 2008-04-01 Allergan, Inc. Method of enhancing hair growth
US8758733B2 (en) 2002-02-04 2014-06-24 Allergan, Inc. Topical treatment for chemotherapy induced eyelash loss or hypotrichosis using prostamide F2 alpha agonists
BR0202157A (pt) * 2002-06-07 2005-04-12 Univ Minas Gerais Peptìdeo obtido de veneno escorpião para uso como agente hipotensivo
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
JP2005511607A (ja) * 2003-07-10 2005-04-28 アラーガン、インコーポレイテッド ＥＰ２受容体作動剤としてのω−シクロアルキル１７−ヘテロアリールプロスタグランジンＥ２類似体
US8076060B2 (en) * 2003-08-04 2011-12-13 Emil William Chynn Vaccination and immunotherapy as new therapeutic modalities in the treatment of glaucoma
US7101904B2 (en) * 2004-08-10 2006-09-05 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US7906552B2 (en) 2004-08-10 2011-03-15 Allergan, Inc. Cyclopentane heptan(ENE)OIC acid, 2-heteroarylalkenyl derivatives as therapeutic agents
DK1960353T3 (da) 2005-11-03 2014-05-26 Allergan Inc Prostaglandiner og analoger som midler til sænkning af intraokulært tryk
CN103804338A (zh) 2006-02-07 2014-05-21 株式会社·R-技术上野 用于制备前列腺素衍生物的方法
US8722739B2 (en) 2008-10-29 2014-05-13 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US8623918B2 (en) * 2008-10-29 2014-01-07 Novaer Holdings, Inc. Amino acid salts of prostaglandins
US20110293549A1 (en) 2009-02-03 2011-12-01 Athena Cosmetics, Inc. Composition, method and kit for enhancing hair
MX361709B (es) 2009-11-09 2018-12-07 Allergan Inc Composiciones y metodos para estimular el crecimiento del cabello.
US9149484B2 (en) 2009-11-09 2015-10-06 Allergan, Inc. Compositions and methods for stimulating hair growth
US8783923B2 (en) * 2010-03-18 2014-07-22 Chung Yuan Christian University Auto lamp structure
US8859616B2 (en) 2011-01-21 2014-10-14 Allergan, Inc. Compounds and methods for enhancing hair growth
CN109568672B (zh) 2013-03-15 2022-06-24 阿勒根公司 含有前列腺胺的眼内植入物
ES2834964T3 (es) 2013-04-01 2021-06-21 Allergan Inc Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida
US9492316B2 (en) 2013-10-31 2016-11-15 Allergan, Inc. Prostamide-containing intraocular implants and methods of use thereof
WO2016176640A1 (en) 2015-04-30 2016-11-03 Allergan, Inc. Cosmetic method and therapeutic use for fat reduction
BR112023001073A2 (pt) 2020-07-21 2023-03-07 Allergan Inc Implante intraocular com alto carregamento de prostamida

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3845115A (en) * 1971-05-04 1974-10-29 Upjohn Co 15-lower alkoxy pgf compounds
US3781325A (en) * 1971-05-04 1973-12-25 Upjohn Co 15-methoxy-pgf2a
BE786251A (fr) * 1971-07-14 1973-01-15 Ici Ltd Nouveaux derives du cyclopentane
US3980642A (en) * 1972-07-13 1976-09-14 Pfizer Inc. 15-Substitute D-ω-pentanorprostaglandins
US4102894A (en) * 1975-11-19 1978-07-25 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
US3974213A (en) * 1972-07-13 1976-08-10 Pfizer Inc. 13,14-Dihydro-15-substituted-ω-pentanorprostaglandins
US4113723A (en) * 1972-07-13 1978-09-12 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
US3956284A (en) * 1972-07-13 1976-05-11 Pfizer Inc. Heterocyclic 15-substituted-ω-pentanorprostoglandins
DE2365767A1 (de) * 1972-07-13 1976-04-15 Pfizer Neue prostaglandinanaloge und verfahren zu deren herstellung
US3984424A (en) * 1972-11-08 1976-10-05 Pfizer Inc. P-biphenyl esters of 15-substituted-ω-pentanorprostaglandins
US4036832A (en) * 1974-07-03 1977-07-19 Pfizer Inc. 15-Substituted-ω-pentanorprostaglandins
IT1053781B (it) * 1974-09-25 1981-10-10 Erba C S P A Ora Farmitalia Omega nor cicloalcil 13.14 deidro prostaglandine
IT1088966B (it) * 1977-11-15 1985-06-10 Erba Carlo Spa 13,14-dideidro-prostaglandine
DE3125271A1 (de) * 1981-06-24 1983-01-13 Schering Ag, 1000 Berlin Und 4619 Bergkamen (delta)(pfeil hoch)8(pfeil hoch),(pfeil hoch)9(pfeil hoch)-prostaglandinderivate, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
GB8329559D0 (en) * 1983-11-04 1983-12-07 Erba Farmitalia Furyl derivatives of 16-substituted prostaglandins preparations
US5321128A (en) * 1988-09-06 1994-06-14 Kabi Pharmacia Ab Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
CA2021316C (en) * 1989-07-27 2000-10-24 Ming Fai Chan Intraocular pressure reducing 11-acyl prostaglandins
US5034413A (en) * 1989-07-27 1991-07-23 Allergan, Inc. Intraocular pressure reducing 9,11-diacyl prostaglandins
US4994274A (en) * 1989-07-27 1991-02-19 Allergan, Inc. Intraocular pressure reducing 11,15-diacyl prostaglandins and method of using
US5028624A (en) * 1989-07-27 1991-07-02 Allergan, Inc. Intraocular pressure reducing 9,15-diacyl prostaglandins
US5352708A (en) * 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5834498A (en) 1992-09-21 1998-11-10 Allergan Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
AU665287B2 (en) * 1992-12-21 1995-12-21 Alcon Laboratories, Inc. Prostaglandin combinations in glaucoma therapy
US5545665A (en) * 1993-12-28 1996-08-13 Allergan Cyclopentane(ene) heptenoic or heptanoic acids and derivatives thereof useful as therapeutic agents
EP0825980B1 (de) * 1995-05-18 2001-07-04 Allergan Sales, Inc. 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes
US5741810A (en) * 1996-02-29 1998-04-21 Allergan Cyclopentane heptan(ene)oic acid, 2- heteroarylalkenyl derivatives as therapeutic agents

Also Published As

Publication number Publication date
US6573390B2 (en) 2003-06-03
US20010029304A1 (en) 2001-10-11
AU1958597A (en) 1997-09-16
CN1218400A (zh) 1999-06-02
AU725145B2 (en) 2000-10-05
ES2178756T3 (es) 2003-01-01
US5741810A (en) 1998-04-21
KR19990087352A (ko) 1999-12-27
WO1997031895A2 (en) 1997-09-04
DE69714023D1 (en) 2002-08-22
US6680337B2 (en) 2004-01-20
CA2247208A1 (en) 1997-09-04
JP4226650B2 (ja) 2009-02-18
HK1017671A1 (en) 1999-11-26
CN1133434C (zh) 2004-01-07
JP2000506139A (ja) 2000-05-23
ATE220664T1 (de) 2002-08-15
US6096902A (en) 2000-08-01
WO1997031895A3 (en) 1997-12-18
DE69714023T2 (de) 2003-03-13
EP0888298A2 (de) 1999-01-07
US20030191178A1 (en) 2003-10-09
BR9707892A (pt) 1999-07-27

Similar Documents

Publication Publication Date Title
EP0888298B1 (de) Cyclopentane heptan(ene)säure, 2-heteroarylalkenylderivate als therapeutisches mittel
US6248773B1 (en) Cyclopentane heptan(ene)oic acid, 2-heteroarylalk(en)yl derivatives as therapeutic agents
US6204287B1 (en) Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
US5834498A (en) Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
EP0825980B1 (de) 2-heteroarylalkenylderivate der cyclopentano-heptan(heptaen)säure als therapeutisches mittel zur behandlung des erhöhten augeninnendruckes
US20040044045A1 (en) Cyclopentane heptan(ene)oic acid, 2-heteroarylalkenyl derivatives as therapeutic agents
EP1320521B1 (de) 2-thiocarbamoyloxy- und 2-carbamoyloxy-derivate von cyclopentyl-heptan(en)säure als therapeutische mittel
US6248783B1 (en) Cyclopentane 1-hydroxy alkyl or alkenyl-2-one or 2-hydroxy derivatives as therapeutic agents
AU2001285196A1 (en) 2-thiocarbamoyloxy and 2-carbamoyloxy derivatives of cyclopentyl-heptan(ene)oic acid as therapeutic agents
US20070219256A1 (en) Cyclopentane heptan(ene)oic acid, 2-thiocarbamoyloxy and 2-carbamoyloxy compounds as therapeutic agents

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19980925

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 980925;LT PAYMENT 980925;LV PAYMENT 980925;RO PAYMENT 980925;SI PAYMENT 980925

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: ALLERGAN SALES, INC.

17Q First examination report despatched

Effective date: 20000927

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07C 405/00 A, 7A 61K 31/559 B, 7A 61P 27/06 B

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RIC1 Information provided on ipc code assigned before grant

Free format text: 7C 07C 405/00 A, 7A 61K 31/559 B, 7A 61P 27/06 B

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: AL PAYMENT 19980925;LT PAYMENT 19980925;LV PAYMENT 19980925;RO PAYMENT 19980925;SI PAYMENT 19980925

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020717

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020717

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020717

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020717

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020717

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020717

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20020717

REF Corresponds to:

Ref document number: 220664

Country of ref document: AT

Date of ref document: 20020815

Kind code of ref document: T

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69714023

Country of ref document: DE

Date of ref document: 20020822

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20021017

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20021017

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20021017

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
ET Fr: translation filed
LTIE Lt: invalidation of european patent or patent extension

Effective date: 20020717

REG Reference to a national code

Ref country code: ES

Ref legal event code: FG2A

Ref document number: 2178756

Country of ref document: ES

Kind code of ref document: T3

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030220

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20030228

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20030422

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: ES

Payment date: 20080226

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20080227

Year of fee payment: 12

Ref country code: GB

Payment date: 20080227

Year of fee payment: 12

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20080218

Year of fee payment: 12

Ref country code: DE

Payment date: 20080331

Year of fee payment: 12

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20090220

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20091030

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090901

REG Reference to a national code

Ref country code: ES

Ref legal event code: FD2A

Effective date: 20090221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090220

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090302

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090221

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20090220